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Abstract 
Purpose: To formulate and study the kinetics of delivery and retention of three halofuginone (HF) gels 
via different wall layers of an ex vivo model mimicking urethral tissue. 
Methods: Three HF hydrogels (a, b and c) of the same concentration (0.03 % w/v) incorporating 
different levels of sodium carboxymethyl cellulose (Na-CMC), were prepared. The viscosity of the 
different gels was studied at 37 °C and at room temperature. The release of HF from these hydrogels 
and its diffusion into urethral tissue were evaluated using a new ex vivo model mimicking human 
urethral tissue. The amount of HF was determined by HPLC method. 
Results: The release of HF increased with increasing viscosity and duration of contact. Gel c showed 
the best drug release after 2 h of diffusion, with 65.7 % HF in the wall of the ureter. The model showed a 
uniform distribution of the drug throughout the ureter tissue. In comparison, HF was not detected in the 
receiver compartment until 2 h. 
Conclusion: Topical HF gel application is a suitable solution for the potential treatment of urethral 
stricture and/or recurrence. The formulation and characterization of the ureter model should facilitate the 
development of new therapeutics for urethral diseases. 
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The development of urethral stricture is a fibrotic 
process. It is associated with the deposition of 
non-compliant scar tissue in the spongy zone 
surrounding the urethra, and it leads to a 
decrease in luminal diameter [1]. The spongy 
tissue surrounds the strictured urethra and 
modifies the collagen content. Therefore, there is 
an unusually high proportion of type 1 collagen, 
relative to type 3 which usually dominates in a 
scar [2]. These strictures are usually due to 
chronic or recurrent infection, instrumentation, 
catheterization, external trauma and urethritis [3]. 
They result in blocked micturition in young men, 
as well as frequent recurrence after the initial 
treatment. When a stricture occurs, the patients 
need frequent hospitalization, which entails 
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increased cost of healthcare in addition to a 
decrease in life quality [4]. Conventional and 
effective treatment strategies for urethral 
strictures include visual internal urethrotomy and 
urethral dilation. However, recurrence occurs in 
many patients just because no treatments can 
prevent these relapses [1]. 
 
Halofuginone resembles febrifugine, an alkaloid 
originally isolated from Dichroa febrifuga, which 
is a potent inhibitor of collagen α1 type 1 gene 
expression and extracellular matrix deposition 
[5]. So far, no other specific inhibitor of collagen 
type 1 synthesis is known apart from HF [6-8]. 
This inhibition is usually studied in cell cultures 
and in animal models of fibrosis in which 
abnormal collagen deposition takes place [8,9]. It 
reduces fibrosis and adhesion formation in many 
human tissues [6,7]. Relying on its mode of 
action, HF is used to prevent and treat various 
diseases caused by excessive type 1 of collagen 
synthesis such as scleroderma [8], liver cirrhosis 
[10], adhesion after abdominal surgery [11], 
esophageal stricture [12] and burn scar [9]. 
 
Animal studies have demonstrated that HF is a 
promising treatment for limiting urethral stricture 
formation and recurrence [13]. The present study 
was carried out to develop effective treatment of 
urethral stricture in humans. Due to the 
effectiveness of local application of HF in dermal 
disease, and difficulties associated with oral 
therapy in humans, endo-urethral topical gel was 
used. The gel was based on NaCMC a non-toxic 
natural polysaccharide, so as to ensure sufficient 
contact time with the urethra wall [14]. 
 
The histological resemblance between the 
urethra tissue and human ureter wall was 
exploited in studying diffusion of HF by using the 
ureter as an ex vivo model to simulate the 
urethra. 
 
The study was designed to obtain and evaluate a 
gel formulation permitting optimal retention of HF 
in the wall of the human ureter using a novel 






Standard HF hydrobromide and carboxymethyl 
cellulose were products of Discovery of Fine 
Chemicals, Dorset, and Prolabo, Paris, 
respectively. Other chemicals and their sources 
included imipramine HCL (Sigma Ultra (England), 
HPLC-grade acetonitrile and propane-2-ol (Lab 
Scan); ammonium acetate, sodium carbonate 
and trypsin (Sigma Aldrich); acetic acid (Merck), 
and triethylamine (Fluka). Others were 
ammonium sulfate (Riedel-de Haên), and 
phosphate buffered saline (Prolabo, 
Paris).Purified water was produced using 
Millipore (Arium 611DI/611UV) equipment in our 
laboratory. All the othersc hemicals used were of 
analytical grade. 
 
Human ureter tissue 
 
Human ureter was got fresh during kidney 
transplantation at Sahloul Hospital, Sousse, 
Tunisia. The ureter is usually available in the 
kidney transplanting departments because the 
donor's kidney is always removed through a long 
ureter with some portions trimmed off according 
to the receiver anatomy. These portions may be 
retrieved after obtaining the donor's consent, and 
preserved in Eurocollins® solution. The Research 
Ethics Committee of Sahloul University Hospital 
of Tunisia approved gave ethical approval for the 
use of the ureter as an ex vivo model (ref no. 
13218). The guidelines followed were in 
accordance with the principles set in Declaration 
of Helsinki [15]. 
 
The ureter was divested of surrounding excess 
adipose tissue. Depending on the experience, 
the ureter was opened to a rectangular shape to 
enable the study of diffusion kinetics, or 
maintained intact for performing endourethral 
instillation. All samples were immersed in 
physiological saline to eliminate traces of 
preservation fluid, and dried with Whatman filter 
paper no. 1. 
 
Ureter model used 
 
Due to the histological resemblance between the 
human urethra and ureter wall, the latter was 
used as an ex vivo model to simulate human 
urethra in the study of the diffusion of HF. Thus, 
the living human ureter was used to predict the 
diffusion of HF through the urethra wall and its 
three-dimensional distribution in this tissue. The 
study was conducted in two parts. The first part 
investigated passive diffusion of the drug into the 
tissue and the absence of passage in the 
recipient compartment. It consisted of evaluating 
the release of HF from the gel, and its retention 
in the ureter tissue using a diffusion cell. The 
second part studied the three-dimensional 
homogeneous diffusion of HF through the tubular 
shape of the human ureter. 
 
Preparation of HF hydrogels. 
 
Three different gels a, b and c were prepared by 
varying the concentrations of Na-CMC at fixed 
concentration of HF (Table 1). The pH of the 
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three gels ranged between 7 and 7,5. The 
hydrogels were packed into glass tubes securely 
closed and stored at 4°C prior to use. 
 
Table 1: Composition of HF hydrogel 
 
Component   (% 
w/v) 
Gel a Gel b Gel c 
HF (%) 0.03  0.03 0.03 
NaCMC (%) 4  6  7  
Distilled water Qs* Qs Qs 




For each of the gels, viz, a, b, and c, three 
measurements of viscosity were made at 37 °C 
and at room temperature, using a field brook field 
DV-III with spindle LV61. The impact of gel 
viscosity on tissue diffusion was then studied. 
 
Ex vivo permeability studies  
 
The studies were performed using a modified 
diffusion cell (exposed area: 50 mm2). The ureter 
samples were subsequently sandwiched 
between the receiver and donor compartments of 
the diffusion cell, with the inner part of ureter 
opposite the donor chamber, while the outer part 
side is faced the receptor chamber. Phosphate 
buffer saline (PBS) pH 7.4 was used as a 
receptor media and the cell contents were 
maintained at a temperature of 37 ± 1 ◦C, with 
constant stirring at 100 rpm on a small magnetic 
bar. The donor compartment was then filled with 
300 mg of gel containing HF at 0.03 % (w/v). The 
receptor interface was blocked with parafilm to 
ensure that the gel did not evaporate. To the 
receiver chamber was added 2.5 ml of PBS at 
30-min intervals up to 120 min. Aliquots of 100 µl 
were periodically sampled from the receptor 
compartment and replaced with an equal volume 
of buffer. The HF contents of the various 
samples of PBS were measured by HPLC using 
an injection volume of 5 µl of receiver 
compartment solution. 
 
Ureter retention studies 
 
During the 120 min study period, the exposed 
areas were removed from diffusion cell at timed 
intervals, and fragments of ureter were rinsed in 
physiological saline to remove excess drug. The 
amount of drug retained in each ureter section 
was measured by HPLC after a step of a liquid-
liquid extraction using isopropanol [16]. 
 
Three dimensional distribution of HF 
 
Fresh ureter was cut into tubular portions of 3 cm 
in length. The HF gel was placed inside each 
portion of the ureter which was then hermetically 
sealed at its two ends with sutures. Each portion 
was placed in a test tube containing PBS at 37 
°C. The wall of the ureter simulated the four 
layers of the urethra while the PBS solution 
simulated the spongy body. After 2 h, the ureters 
were recovered. Excess gel was removed by 
rinsing in physiological saline, and the ureters 
were cut horizontally in two portions. Then 
vertical cuts resulted in 8 portions of area 37 
mm2. The distribution of HF in the ureter wall 
portions, as well as the amount of HF diffused in 




The amounts of HF in the human ureter and in 
the receptor compartment of the cell diffusion in 
the test tube were determined by HPLC [16]. 
Theanalysis was carried out in an Agilent 1200 
HPLC equipped with G1322A degassers, 
G1311A quaternary pump, G1315D diode array 
detector, at an injection volume of 5 µl. The 
HPLC was carried out at 30 °C in a Lichrospher® 
C18,250 x 4 mm, 5-µm column of 4 mm internal 
diameter and 250 mm long; and Lichrospher® 
100RP18 guard column (4 x 4 mm) with 5 µm 
particle size.  
 
Both HF and internal standard (imipramine) were 
eluted in gradient mode, and HF was at 243 nm. 
The HPLC method was successfully validated by 
applying the novel validation protocol using the 
accuracy profile based on a concept of the total 
error. This method is accurate in the range of 0.2 




Data were analyzed using SPSS software, 
version 18. A comparative univariate statistical 
study was conducted to determine the factors 
that influence HF diffusion through the human 
urethra, and subsequent comparison of the 
diffusion through the wall of the urethra in the ex 
vivo model according to the viscosity and/or the 





Ex vivo permeability  
 
Permeability studies showed that HF did not 
diffuse into the receptor compartment of the 
diffusion cell. This implies that HF was retained 
in the ureter tissue for 2 h. 
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Results obtained from viscosity studies at room 
 temperature and at 37° C are shown in Table 2. 
 
Table 2: Viscosity of HF hydrogel formulations 
 
Gel a 




0.1 899 419 
0.1 899 599.9 
0.1 1020 620 
Mean 939.3 546.3 
Gel c 




0.1 8818 4308 
0.1 8878 4799 
0.1 8857 3500 
Mean 8851 4202 
*cPs = centipoise  
 
The viscosity of the three gels decreased at 37 
°C, when compared to their viscosities at room 
temperature. Viscosities also decreased with 
decreases in the amount of the gelling agent 
(Na-CMC). Gel c formula had the most important 
viscosity at 37° C (4202 cPs) and at room 
temperature (8851 cPs). 
 
Ex vivo retention and release study 
 
At the end of the exposure time (0, 30, 60, 90 
and 120 min) each fragment of the ureter was 
ground and the HF was extracted to measure its 
retained proportion within the tissue. The 
accumulated quantities of HF in the wall of the 




Figure 1: Ex vivo release of HF through the human 
wall ureter (n = 5). (◊) = Gel a, (■) = Gel b, () = Gel c  
The curve shows that from the initial applied dose 
(300 mg/50 mm2), the amount of HF diffused into 
the wall increased during the two hours after 
application of the gel, to reach 11.83 μg/cm2 at 
120 min for gel formula c. On the other hand, 
diffusion for gel a did not exceed 10 µg/cm2 (8.26 
µg/cm2) while that of gel b barely exceeded 10 
µg/cm2 (10.59 µg/cm2). 
 










Gel a 5.21  
<10-3 Gel b 6.29 
Gel c 8.29 
 
60 
Gel a 11.47  
<10-3 
 
Gel b 13.41 
Gel c 17.12 
 
90 
Gel a 22.8  
<10-3 Gel b 24.91 
Gel c 28.68 
 
120 
Gel a 45.91  
<10-3 Gel b 58.88 
Gel c 65.74 
 
The amount of HF on the wall of the ureter 
continued to increase with duration of exposure 
time, and with viscosity. After two hours, drug 
permeation was 45.91 %, 58.88 %, and 65.74 % 
for gels a, b, and c, respectively (Table 3). The 
amounts of HF in the ureter wall after 30 min, 60 
min, 90mn and 120 min increased for the three 
formulated gels. 
 
A significant association was found between the 
viscosity and the amount of HF at each period (p 
= 10-3). A comparative study of the retention of 
HF in the ureter wall as a function of three 
different gel viscosities for 30, 60, 90, 120 min 
showed that gel c which had the highest viscosity 
gave a higher amount of a drug release, when 
compared to other two tested gels. Gel c was 
considered as an optimized gel, and it showed 
the best kinetics of diffusion. 
 
Three-dimensional distribution of HF 
 
Gel c was used as the baseline gel in testing the 
spatial dispersion of the drug in the wall of the 
human ureter. The results showed that the 
amount of HF retained in the ureter fragments 
were almost similar, which is an indication that 
the drug was uniformly dispersed in the ureter 
wall after an ex vivo endo-urethral instillation 
(Figure 2). 
 
The results of analysis revealed that HF was not 
detected in the receiver compartment of the 
diffusion cell, and it was also absent in the PBS 
solution following the investigation of the three-
dimensional distribution of HF. 
Gel b 




0.1 2600 1440 
0.1 2400 1380 
0.1 2939 1320 
Mean 2646.3 1380 
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This study was aimed at formulating a model 
hydrogel for delivery of HF, a drug used to treat 
and to prevent urethra stricture. When instilled, 
HF was able to penetrate deep into the urethra, 
and remained there at an effective concentration 
for 2 h. The kinetics of diffusion is important here, 
because the patient should be able to refrain 
from urinating, and in turn eliminating the gel, for 
a maximum of 2 h. Due to lack of in vitro and in 
vivo models targeting the human urethra, studies 
on the urethra were hitherto carried out on 
animal models such as rabbits [13,17] and rats 
[18]. 
 
The urethral model developed in this study can 
be useful for researchers involved in the 
development of potential treatments in urology, 
andrology, oncology, and sexology. The model is 
unique and was not described in earlier studies. 
It will be a valuable and innovative tool for all 
researchers in the field of urethral and penile 
pathologies. 
 
The diffusion of drugs in the tissues is influenced 
by the duration of contact. The longer the 
duration, the better the diffusion. Diffusion is also 
influenced by the nature of the gel used. The gel 
controls the release and diffusion of medications. 
The nature of the gelling agent and the viscosity 
of the gels are determining factors in the release 
of drugs and their diffusion. In the present study, 
the variation in the amount of Na-CMC resulted 
in variations in gel viscosity. Indeed, the delivery 
of drugs in gel formulations is influenced by 
viscosity. Viscosity may directly influence the 
diffusion of the drug at the microstructure level. 
The amount of HF diffused in the wall of the 
ureter depended not only on the duration factor 
but also on the viscosity of the gel used. 
 
It was noticed that the ex vivo release of the drug 
progressed with increases in Na-CMC content. 
This was most likely due to the generation of a 
network of hydrophilic and loose Na-CMC cross-
links [19]. However, high-viscosity gel 
formulations may still manifest significant 
diffusion rates in hydrophilic gels. Thus, the 
performance of drugs in gel formulations are 
influenced by their rheological properties [20]. 
 
It has been postulated that drug release from gel 
formulations varies directly with the square root 
of time [23]. Therefore, the membrane used has 
no significant effect on the release of the drug 
[24]. In this study HF was entirely dissolved in 
the gel. The inverse relation between viscosity 
and drug release has been demonstrated in 
several investigations regarding hydrophobic 
gelling agents [21,22]. In the present study, the 
kinetics of diffusion and the spatial dispersion of 
HF in the human ureter revealed that the chosen 
gel (gel c) could serve as an effective support for 
delivery of HF to urethra stenosis. This result has 
a significant advantage for the patients. In fact, 
systemic side effects of HF crossing blood 
stream should be minimized. A phase I study on 
orally administered HF showed severe 
complications for patients at doses 0.5 to 3.5 
mg/day [25]. 
 
The absence of HF at the receptor compartment 
level in this study is a very encouraging result. 
Indeed, during the transition to phase I study, the 
risk of systemic passage of HF should be very low 




This study has successfully developed a new 
model mimicking the human urethra for 
predicting the diffusion of HF through three gels 
having different viscosities. The findings of this 
study show that hydrogel c with viscosity of 8851 
cPs gave the best kinetics of diffusion of HF 
through the wall of the ureter in the delivery of 
0.03 % (w/v) of the drug. The study also show 
the uniform distribution of HF following a 
tridimensional diffusion study using the new ex 
vivo model developed in this work. Thus, HF gels 
prepared using NaCMC as vehicle is a promising 
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